We are live on
!
Find out more
Pacer Advisors Portfolio holdings
AUM
$35.6B
1-Year Est. Return
18.19%
This Fund
S&P 500
This Quarter
Est. Return
+9.61%
1 Year Est. Return
+18.19%
3 Year Est. Return
+46.13%
5 Year Est. Return
+70.99%
10 Year Est. Return
+394.12%
AUM
$43.5B
AUM Growth
+$8.16B
(+23%)
Cap. Flow
+$4.5B
Cap. Flow
% of AUM
10.34%
Top 10 Holdings %
Top 10 Hldgs %
11.55%
Holding
3,819
New
249
Increased
1,063
Reduced
1,013
Closed
119
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AT&T
T
|
+$424M |
| 2 |
Kenvue
KVUE
|
+$415M |
| 3 |
Cummins
CMI
|
+$374M |
| 4 |
Bunge Global
BG
|
+$310M |
| 5 |
Newell Brands
NWL
|
+$224M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$423M |
| 2 |
Qualcomm
QCOM
|
+$413M |
| 3 |
D.R. Horton
DHI
|
+$401M |
| 4 |
Booking.com
BKNG
|
+$397M |
| 5 |
Phillips 66
PSX
|
+$389M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 17.42% |
| 2 | Energy | 16.95% |
| 3 | Industrials | 12.39% |
| 4 | Healthcare | 10.91% |
| 5 | Technology | 10.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1376
Digi International
DGII
$2.52B
| $18.7K | ﹤0.01% |
585
+446
| +321% | +$12.5K |
|
1377
CareDx
CDNA
$1.82B
| $18K | ﹤0.01% |
+1,698
| New | +$17K |
|
1378
Relay Therapeutics
RLAY
$3.91B
| $17.9K | ﹤0.01% |
+2,157
| New | +$21K |
|
1379
Regenxbio
RGNX
$597M
| $17.6K | ﹤0.01% |
+835
| New | +$14.9K |
|
|
CDMO
1380
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
| $16.4K | ﹤0.01% |
+2,450
| New | +$16.9K |
|
1381
Allogene Therapeutics
ALLO
$566M
| $16.3K | ﹤0.01% |
+3,657
| New | +$15.3K |
|
|
DCPH
1382
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $16K | ﹤0.01% |
+1,016
| New | +$15.6K |
|
1383
Anavex Life Sciences
AVXL
$232M
| $15.9K | ﹤0.01% |
+3,120
| New | +$17.6K |
|
1384
Olema Pharmaceuticals
OLMA
$981M
| $15.5K | ﹤0.01% |
+1,369
| New | +$17.7K |
|
1385
MannKind Corp
MNKD
$1.2B
| $15.4K | ﹤0.01% |
+3,408
| New | +$13.4K |
|
|
DAWN
1386
DELISTED
Day One Biopharmaceuticals
DAWN
| $14.9K | ﹤0.01% |
+902
| New | +$13.5K |
|
1387
Nurix Therapeutics
NRIX
$2.37B
| $14.5K | ﹤0.01% |
+985
| New | +$10.6K |
|
1388
InMode
INMD
$893M
| $14K | ﹤0.01% |
650
-24
| -4% | -$537 |
|
1389
Sportradar
SRAD
$4.44B
| $13.5K | ﹤0.01% |
1,162
+176
| +18% | +$1.86K |
|
1390
Kiniksa Pharmaceuticals
KNSA
$6.07B
| $13K | ﹤0.01% |
+660
| New | +$12.9K |
|
1391
Caribou Biosciences
CRBU
$149M
| $12.9K | ﹤0.01% |
+2,516
| New | +$15.5K |
|
1392
Summit Therapeutics
SMMT
$9.84B
| $12.5K | ﹤0.01% |
+3,029
| New | +$12K |
|
1393
Unity
U
$13.3B
| $12.5K | ﹤0.01% |
468
+86
| +23% | +$2.7K |
|
1394
Qiagen
QGEN
$8.62B
| $11.4K | ﹤0.01% |
259
| – | – |
|
|
EVRI
1395
DELISTED
Everi Holdings
EVRI
| $11.4K | ﹤0.01% |
1,131
+200
| +21% | +$2.07K |
|
1396
Bally's
BALY
$705M
| $11.3K | ﹤0.01% |
814
+191
| +31% | +$2.22K |
|
1397
Rush Street Interactive
RSI
$3.17B
| $10.5K | ﹤0.01% |
1,619
-6
| -0.4% | -$32 |
|
1398
MiMedx Group
MDXG
$645M
| $10.3K | ﹤0.01% |
+1,344
| New | +$10.8K |
|
|
ATXS
1399
DELISTED
Astria Therapeutics
ATXS
| $10.3K | ﹤0.01% |
+732
| New | +$9.12K |
|
1400
iShares MSCI Taiwan ETF
EWT
$9.56B
| $10.1K | ﹤0.01% |
208
-54
| -21% | -$2.5K |
|
Similar funds
SAM
Pacer Advisors's Q1 2024 Portfolio in Review
As of Q1 2024, Pacer Advisors held 3,819 positions worth $43.5B, up 23% from $35.3B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Pacer Advisors deployed $4.5B of net new capital in Q1 2024, opening 249 new positions and adding to 1,063 existing holdings. Its largest new stake was Hanesbrands: 32,772,533 shares worth $190M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 17% of assets, down from 19% a quarter earlier, followed by Energy and Industrials.
On the sell side, the largest reduction was AbbVie, an estimated $423M trimmed.
- Pacer Advisors's largest Q1 2024 buy was Hanesbrands: 32,772,533 shares worth $190M.
- Pacer Advisors added most to AT&T in Q1 2024, an estimated $424M increase.
- Pacer Advisors's biggest Q1 2024 reduction was AbbVie, cutting an estimated $423M.
- Pacer Advisors fully exited Tri Pointe Homes in Q1 2024, selling an estimated $139M.
- Pacer Advisors's ten largest holdings make up 12% of its $43.5B portfolio in Q1 2024.
- Pacer Advisors opened 249 new positions and closed 119 in Q1 2024.
- Pacer Advisors's portfolio value rose 23% quarter-over-quarter to $43.5B.
Based on Pacer Advisors's 13F filing for Q1 2024, filed 10 May 2024.